In the latest quarter, 11 analysts provided ratings for Nevro (NYSE:NVRO), showcasing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Nevro and provided 12-month price targets. The average target is $5.32, accompanied by a high estimate of $7.00 and a low estimate of $4.00. A 20.6% drop is evident in the current average compared to the previous average price target of $6.70.

Interpreting Analyst Ratings: A Closer Look

In examining recent analyst actions, we gain insights into how financial experts perceive Nevro. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of Nevro's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Nevro analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Nevro Better

Unraveling the Financial Story of Nevro

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Negative Revenue Trend: Examining Nevro's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -6.69% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Nevro's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -15.83% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Nevro's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.6%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Nevro's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.56% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Nevro's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.9.

Analyst Ratings: Simplified

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.